[Experimental study on protective effects of curcumin on exaggerated extracellular matrix accumulation of pulmonary fibrosis rats].
OBJECTIVE
To study the protective effects of curcumin on exaggerated extracellular matrix accumulation of pulmonary fibrosis rats.


METHODS
One hundred and forty-four male Sprague-Dawley rats were randomly divided into 6 groups (24 rats in each group). Rats in the model control group, positive medicine group, and high, moderate and low curcumin groups were injected with a single dose of bleomycin by trachea, and rats in sham-model control group with same volume normal saline. One day after the injection, curcumin solution of different dosages (200, 100, 50 mg x kg(-1) x d(-1)) was respectively given to rats in the high, moderate and low curcumin group daily by gastrogavage, while equal volume of normal saline was given to those in the sham-model control group and model control group, and an equal volume of prednisone (0.56 mg x kg(-1) x d(-1)) was given to those in positive medicine control group. On the 7, 14, 28 days, 8 rats per treatment group were randomly killed, the levels of III-collagen, IV-collagen, laminin and hyaluronic acid in the serum were determined, the determination of hydroxyproline in lung homogenates was analyzed, and the lung was incised to make pathological sections which were stained with HE and Mallory.


RESULTS
Curcumin could decreas the levels of III-collagen, IV-collagen, laminin and hyaluronic acid in the serum, and inhihit the proliferation of fibrous tissue.


CONCLUSIONS
Curcumin may play its therapetuic role by leveling down the content of extracellular matrix in rats with pulmonary fibrosis induced by bleomycin.
Zhou
Gang
G
Laboratory of Cell and Biochemistry, Beijing University of Traditional Chinese Medicine, Beijing 100029, China.
Wang
Ji-Feng
JF
Niu
Jian-Zhao
JZ
Lu
Yin-Sheng
YS
Chen
Wei-Tao
WT
Li
Ze-Hua
ZH
Lin
Tong-Xiang
TX
D000818:Animals; D001761:Bleomycin; D001835:Body Weight / Q000187:drug effects; D024061:Collagen Type III / Q000097:blood; D024141:Collagen Type IV / Q000097:blood; D030024:Curcuma / Q000737:chemistry; D003474:Curcumin / Q000302:isolation & purification / Q000494:pharmacology*; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology; D016326:Extracellular Matrix Proteins / Q000097:blood* / Q000378:metabolism; D006820:Hyaluronic Acid / Q000097:blood; D006909:Hydroxyproline / Q000097:blood / Q000378:metabolism; D007797:Laminin / Q000097:blood; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D010946:Plants, Medicinal / Q000737:chemistry; D020011:Protective Agents / Q000494:pharmacology; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D024061:Collagen Type III; D024141:Collagen Type IV; D004365:Drugs, Chinese Herbal; D016326:Extracellular Matrix Proteins; D007797:Laminin; D020011:Protective Agents; D001761:Bleomycin; D006820:Hyaluronic Acid; D003474:Curcumin; D006909:Hydroxyproline